BSE Sensex

The Medicines Control Council has ordered JSE-listed Enaleni Pharmaceuticals to halt production of medicines at its Durban facility because it does not meet manufacturing standards, it emerged yesterday.

The Medicines Control Council has ordered JSE-listed Enaleni Pharmaceuticals to halt production of medicines at its Durban facility because it does not meet manufacturing standards, it emerged yesterday.

The Medicines Control Council has ordered JSE-listed Enaleni Pharmaceuticals to halt production of medicines at its Durban facility because it does not meet manufacturing standards, it emerged yesterday.

A new and cheaper generic Aids drug manufactured by one of India's largest pharmaceutical companies could be on the cards for millions of South Africans suffering from HIV/Aids.

Bowing to huge international pressure, major pharmaceutical companies have made significant efforts to make their patented antiretroviral drugs available in Africa while ensuring that they - not generic manufacturers - maintain market control in the continent.

In a move that could affect HIV-positive people on treatment in developing countries, an Indian generic drug manufacturer voluntarily withdrew its drugs from the World Health Organisation's (WHO) list of approved HIV medicines.

Indian medical experts see the hand of powerful Western drug manufacturers in the World Health Organisation's withdrawals of its recommendations, this month and earlier in May, for some of India's cheap and popular combination drugs against HIV/AIDS using generic 'copycats.'

The Medicines Control Council is to launch an investigation into five generic AIDS drugs made by Indian drug giant Ranbaxy and registered in SA.

The Medicines Control Council (MCC) has declared a generic version of antiretroviral (ARV) Duovir undesirable and ordered a recall, the manufacturer confirmed on Thursday.

The World Health Organisation today announced that it has removed three antiretroviral products manufactured by the Indian company Ranbaxy from its list of prequalified antiretroviral products. Prequalification has been suspended because site visits within the past two weeks to contract research organisations that carried out bioequivalence studies for Ranbaxy revealed non-compliance with international standards of Good Clinical Practices and Good Manufacturing Practices.